1. A communication terminal having one or more one-touch-dial buttons, the communication terminal comprising:
a one-touch-dial registration unit that allows destination data to be registered therein so as to be associated with the one or more one-touch-dial buttons; and
a display that displays a screen showing a one-touch-dial registration; and
a control unit that, in response to an operation of the one or more one-touch-dial buttons, makes destination data register in the one-touch-dial registration unit so as to be associated with the one or more one-touch-dial buttons, based on a selection of the one-touch-dial registration from the screen showing the one-touch-dial registration on the display, in a case where destination data has not been registered in the one-touch-dial registration unit in relation to the one or more one-touch-dial buttons operated.
2. The communication terminal according to claim 1, wherein the display displays the screen showing selection information of the one-touch-dial registration in a case where destination data has not been registered in the one-touch-dial registration unit.
3. A dial registration method for a communication terminal having one or more one-touch-dial buttons, the dial registration method comprising the steps of:
registering destination data in a one-touch-dial registration unit so as to be associated with the one or more one-touch-dial buttons; and
in response to an operation of the one or more one-touch-dial buttons, making destination data register in the one-touch-dial registration unit so as to be associated with the one or more one-touch-dial buttons, based on a selection of the one-touch-dial registration from a screen showing the one-touch-dial registration, in a case where destination data has not been registered in the one-touch-dial registration unit in relation to the one or more one-touch-dial buttons operated.
4. A dial registration program for a communication terminal having one or more one-touch-dial buttons, the dial registration program allowing an information processing unit to execute the steps of:
registering destination data in a one-touch-dial registration unit so as to be associated with the one or more one-touch-dial buttons; and
in response to an operation of the one or more one-touch-dial buttons, making destination data register in the one-touch-dial registration unit so as to be associated with the one or more one-touch-dial buttons, based on a selection of the one-touch-dial registration from a screen showing a one-touch-dial registration, in a case where destination data has not been registered in the one-touch-dial registration unit in relation to the one or more one-touch-dial buttons operated.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pharmaceutical composition comprising the EGFR kinase inhibitor erlotinib, or a salt thereof, and capecitabine, in a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, additionally comprising one or more other anti-cancer agents.
3. A composition in accordance with claim 3, wherein said other anti-cancer agent is a member selected from the group consisting of alkylating drugs, antimetabolites, microtubule inhibitors, podophyllotoxins, antibiotics, nitrosoureas, hormone therapies, kinase inhibitors, activators of tumor cell apoptosis, and antiangiogenic agents.
4. A method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of the EGFR kinase inhibitor erlotinib and capecitabine.
5. The method of claim 4, wherein the patient is a human that is being treated for cancer.
6. The method of claim 4, wherein erlotinib and capecitabine are co-administered to the patient in the same formulation.
7. The method of claim 4, wherein erlotinib and capecitabine are co-administered to the patient in different formulations.
8. The method of claim 4, wherein erlotinib and capecitabine are co-administered to the patient by the same route.
9. The method of claim 4, wherein erlotinib and capecitabine are co-administered to the patient by different routes.
10. The method of claim 4, wherein erlotinib is administered to the patient by parenteral or oral administration.
11. The method of claim 4, wherein capecitabine is administered to the patient by parenteral or oral administration.
12. The method of claim 4, additionally comprising one or more other anti-cancer agents.
13. The method of claim 12, wherein the other anti-cancer agents are selected from an alkylating agent, cyclophosphamide, chlorambucil, cisplatin, carboplatin, busulfan, melphalan, carmustine, streptozotocin, triethylenemelamine, mitomycin C, an anti-metabolite, methotrexate, etoposide, 6-mercaptopurine, 6-thiocguanine, cytarabine, 5-fluorouracil, dacarbazine, an antibiotic, actinomycin D, doxorubicin, daunorubicin, bleomycin, mithramycin, an alkaloid, vinblastine, paclitaxel, a glucocorticoid, dexamethasone, a corticosteroid, prednisone, a nucleoside enzyme inhibitors, hydroxyurea, an amino acid depleting enzyme, asparaginase, leucovorin, and a folic acid derivative.
14. The method of claim 4, wherein the tumors or tumor metastases to be treated are selected from lung cancer, colorectal cancer, NSCLC, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous melanoma, intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal region cancer, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulval carcinoma, Hodgkin’s Disease, esophagus cancer, small intestine cancer, endocrine system cancer, thyroid gland cancer, parathyroid gland cancer, adrenal gland cancer, soft tissue sarcoma, urethral cancer, penis cancer, prostate cancer, bladder cancer, kidney cancer, ureter cancer, renal cell carcinoma, renal pelvis carcinoma, mesothelioma, hepatocellular cancer, biliary cancer, chronic leukemia, acute leukemia, lymphocytic lymphoma, CNS neoplasm, spinal axis cancer, glioma, brain stem glioma, glioblastoma multiforme, astrocytoma, schwannoma, ependymoma, medulloblastoma, meningioma, squamous cell carcinoma and pituitary adenoma tumors or tumor metastases, including refractory versions thereof.
15. The method of claim 14, wherein the tumors or tumor metastases to be treated are colorectal cancer tumors or tumor metastases.
16. The method of claim 14, wherein the tumors or tumor metastases to be treated are breast cancer tumors or tumor metastases.
17. The method of claim 14, wherein the tumors or tumor metastases to be treated are epidermal cancer tumors or tumor metastases.
18. The method of claim 4, wherein the administering to the patient is simultaneous.
19. The method of claim 4, wherein the administering to the patient is sequential.
20. A method for the treatment of cancer, comprising administering to a subject in need of such treatment a first amount of the EGFR kinase inhibitor erlotinib, or a pharmaceutically acceptable salt thereof; and a second amount of capecitabine; wherein at least one of the amounts is administered as a sub-therapeutic amount.